Teva Pharma Soars to 5-Year Highs
Update: 2025-12-26
Description
Teva Pharmaceuticals stock is surging, with a 40% increase over the past year, reaching a five-year high of $31.75. The company received a perfect 100% buy rating from Barchart, driven by strong technical momentum. Tevas Trend Seeker buy signal on October 29th sparked a nearly 57% jump, with its relative strength index at 84. Wall Street analysts and individual investors are bullish, with price targets ranging from $20 to $40. Teva, a global leader in generic and branded drugs, has a market cap of $36.4 billion and is expected to grow earnings by 6% this year. With low short interest and steady support around $31.50, Teva offers smart international diversification for portfolios tracking pharma trends.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
